End-stage renal disease (ESRD) affects approximately 800,000 Americans and requires lifelong renal replacement therapy. The overwhelming majority — 85% — receive in-center hemodialysis (HD): three sessions per week, 3.5–4 hours each, at a dialysis center. Yet the evidence base for home-based dialysis alternatives — home hemodialysis (HHD) and peritoneal dialysis (PD) — is compelling and has been for decades. Home modalities produce better survival, better cardiovascular outcomes, better quality of life, lower rates of hospitalization, and lower total cost of care. In 2026, the gap between evidence and practice remains vast — but new technology, policy changes, and patient demand are beginning to narrow it.
The Outcomes Evidence: Why Home Is Better
The superiority of home dialysis modalities over conventional in-center three-times-weekly HD is supported by multiple lines of evidence:
- Survival: A 2020 analysis of 11,628 propensity-matched patients in the USRDS database found HHD associated with 23% lower all-cause mortality than in-center HD at 2 years. PD showed 12% lower mortality at 2 years.
- Cardiovascular outcomes: Nocturnal HHD (6 nights/week, 8 hours/night) produces LVH regression in 70% of patients with baseline LVH — a finding not reproducible with standard in-center HD, which does not provide adequate clearance to achieve physiological hemodynamics.
- Phosphorus and volume control: More frequent, longer dialysis sessions achieve phosphorus and fluid control superior to standard HD, reducing the need for phosphate binders and fluid restriction.
- Quality of life: Meta-analyses consistently find higher KDQOL (Kidney Disease Quality of Life) scores in HHD and PD patients vs. in-center HD, driven by schedule flexibility, reduced fatigue after treatments, and absence of travel burden.
Why Only 15% of Patients Choose Home Dialysis
If outcomes are better, why does in-center HD dominate? Multiple barriers converge:
- Lack of clinician training: Many nephrologists were not trained in HHD during fellowship, lack confidence in training patients, and have inadequate home dialysis nurse support staff.
- Dialysis center financial incentives: Large dialysis organizations (DaVita, Fresenius) generate revenue primarily from in-center patients; home dialysis is less profitable per patient session.
- Patient awareness: Most ESRD patients are first seen in inpatient settings (starting dialysis urgently through a tunneled catheter) and default to the path of least resistance — in-center HD — without awareness of home alternatives.
- Technology complexity: Traditional HHD machines (e.g., Fresenius 2008K@home) required extensive patient training, water treatment systems, and caregiver involvement — barriers for elderly or disabled patients.
New Technology: NxStage and Outset Medical Tablo
The technology barrier has been substantially addressed by two home-designed HHD systems:
- NxStage System One (now Fresenius NxStage): A portable, cartridge-based system that uses pre-made sterile dialysate bags rather than requiring on-site water treatment. Weight: 35 lbs (portable). Can be transported in a car for vacation dialysis. FDA cleared 2005; now the most widely used HHD system in the US. In 2025, a 5th-generation cartridge design reduced setup time from 45 to 22 minutes.
- Outset Medical Tablo: A compact, touchscreen-guided system that purifies tap water on-demand using a built-in ultrapure filtration system, eliminating the need for water delivery or storage. Tablo won FDA clearance in 2020 and has been adopted by 380+ hospitals and home programs. In 2026, the new Tablo Gen 2 adds automated documentation and integration with EHR platforms including Epic and Cerner, reducing nursing documentation burden by 60%.
Policy Changes Driving Home Dialysis Adoption
The CMS ESRD Treatment Choices (ETC) Model, launched in 2021 and extended through 2026, provides financial incentives to dialysis facilities that increase home dialysis rates — shifting the economic calculus for large dialysis organizations. CMS also increased reimbursement for home dialysis training sessions in 2023, improving the business case for training programs. The Biden administration's executive order on increasing home dialysis access has maintained attention on this policy priority through 2025.
Conclusion
The case for home dialysis is overwhelming — better outcomes, better quality of life, lower cost. The barriers are real but surmountable: technology is improving, policy is shifting, and patient awareness is growing. The 15% home dialysis rate of 2024 needs to look like 30–40% by 2030 if US ESRD care is to reflect the best available evidence. The tools to get there now exist. Healthcare facilities can find relevant diagnostic equipment in our catalog.
